Natriumoxybat (Sodium Oxybate)

Sodium Oxybate, the active ingredient in Natriumoxybat, is a gamma‑hydroxybutyrate (GHB) derivative presented as an oral formulation for oral use. It is indicated for the treatment of narcolepsy with cataplexy in adult patients and helps improve nighttime sleep quality and reduce daytime sleepiness.

GNH USA supplies Natriumoxybat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures reliable delivery across multiple continents, adhering to stringent import and export standards.

Sodium Oxybate is used in the management of sleep‑wake disorders, primarily narcolepsy. - Narcolepsy with cataplexy: reduces the frequency and severity of cataplexy attacks. - Narcolepsy: improves nighttime sleep consolidation, leading to better daytime alertness. - Excessive daytime sleepiness associated with narcolepsy: decreases subjective sleepiness scores.

Sodium Oxybate may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Nausea: mild stomach upset. - Headache: transient cranial pain. - Dizziness: sensation of light‑headedness. Serious or Rare Side Effects: - Respiratory depression: reduced breathing rate, potentially life‑threatening. - Seizures: occurrence of convulsive episodes. - Abuse potential: risk of dependence and misuse.

When prescribing Natriumoxybat, several safety considerations should be observed. - Avoid use in patients with severe obstructive sleep apnea: increased risk of respiratory compromise. - Monitor respiratory function during initiation: watch for hypoventilation. - Do not combine with alcohol or other CNS depressants: additive sedation. - Use caution in hepatic impairment: reduced clearance may increase exposure. - Contraindicated in pregnancy: potential fetal harm; discuss alternatives. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Sodium Oxybate can interact with other medicines, requiring careful management. Major Interactions (Avoid): - Alcohol: additive central nervous system depression. - Opioids: synergistic respiratory depression. - Benzodiazepines: enhanced sedation and risk of overdose. Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase risk of serotonin syndrome. - Antihistamines: may augment sedative effects. - CYP2C19 inhibitors: can raise sodium oxybate plasma levels.